Congress frequently seeks advice from experts in a wide variety of industries. In theory, this expert testimony helps lawmakers craft better, more nuanced legislation. Sometimes these "expert" witnesses aren't especially knowledgeable. Even worse, sometimes they mislead lawmakers in the hope of advancing legislation that benefits their own companies, even if it hurts the country. That's precisely what happened in June, when the House Judiciary Committee held a hearing to investigate whether patenting practices in the pharmaceutical industry are driving up drug prices. The post Fresenius Says to Congress, ‘Do as I Say Not as I Do’ on Drug Patents appeared first on IPWatchdog.com | Patents & Intellectual Property Law .